Other languages Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Real-time Estimate Cboe BZX Other stock markets 01:04:25 2024-05-22 pm EDT			5-day change	1st Jan Change
6.19 ^USD	+1.48%		-1.75%	+38.57%

May. 16	Transcript : Ocular Therapeutix, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
May. 07	Earnings Flash (OCUL) OCULAR THERAPEUTIX Posts Q1 Revenue $14.8M, vs. Street Est of $15.4M	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ocular Therapeutix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07
Ocular Therapeutix, Inc. Announces Positive Topline Phase 1 Data for AXPAXLI? in Diabetic Retinopathy	Apr. 18
Ocular Therapeutix, Inc. Announces Executive Changes	Apr. 15
Ocular Therapeutix, Inc. Announces CEO Changes	Apr. 15
Ocular Therapeutix, Inc. Announces Positive Phase 2 PAXTRAVA? Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting	Apr. 06
Ocular Therapeutix Files Shelf for Common Stock Sale by Stockholders; Shares Fall After Hours	Mar. 25
Ocular Therapeutix Q4 Loss Widens, Revenue Rises -- Shares Down After Hours	Mar. 11
Ocular Therapeutix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 11
Ocular Therapeutix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 11
Ocular Therapeutix Launches $325 Million Private Placement; Makes Board, Management Changes, Shares Rise	Feb. 22
Ocular Therapeutix, Inc. Announces Management Changes	Feb. 22
AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority for DEXTENZA	Feb. 19
Ocular Therapeutix, Inc. Appoints Steve Meyers as Chief Commercial Officer	Feb. 15
Ocular Therapeutix Says First Subjects Screened in Phase 3 Clinical Trial of Wet AMD Treatment	Feb. 13
Ocular Therapeutix, Inc. Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of Axpaxli in Wet Amd	Feb. 13
Sector Update: Health Care Stocks Slipping Thursday Afternoon	Jan. 25
Ocular Therapeutix Shares Rise as US FDA Modifies Enrollment Criteria, Drug Dosage for Axitinib Pivotal Study	Jan. 25
Ocular Therapeutix Announces FDA Agreement to Amend Special Protocol Assessment for Pivotal Clinical Trial of Axpaxli in Wet AMD	Jan. 25
Ocular Therapeutix Raises $115.1 Million in Common Stock Offering; Shares Rise After Hours	Dec. 18
Top Premarket Decliners	Dec. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Ocular Therapeutix, Inc.

Equities

OCUL

US67576A1007

Other languages

Filters